Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Mark Bartlett who wrote (7888)	10/24/2001 7:06:34 PM
From: Cal Gary	Read Replies (1) \| Respond to of 14101

An after hours cross. Month end, index cleanup or fund movement??? Humm. 16:52:30 T 4.260 -.140 45000 2 DS 2 DS 16:52:30 T 4.260 -.140 61 2 DS 2 DS

To: Mark Bartlett who wrote (7888)	10/25/2001 2:39:53 AM
From: Cal Gary	Read Replies (1) \| Respond to of 14101

Hi Mark The following clips are from a LOR NR from last year. It contains the results of Phase I/II of Virulizin for Pancreatic cancer. LOR investors are still waiting for a formal NR that Virulizin Phase III will begin. That's almost 16 months and counting, after the Phase II results were released. The header: JUNE 26, 2000 TSE: LOR NASDAQ OTC BB: LORFF TORONTO, CANADA - June 26, 2000 - Lorus Therapeutics Inc. (Lorus) announced today that a completed meta-analysis of three Phase I/II studies of Virulizin® showed that the drug had demonstrated clinical activity (such as increasing survival rate and preserving quality of life) and was well tolerated by patients. Based on these encouraging findings, Lorus plans to file an investigational new drug application (IND) later in the year in preparation for a pivotal Phase III clinical trial. Below, the survival times are better than traditional first line, but marginally. These must be very sick people who participated in the LOR pancrease cancer clinicals. It does appear to help, but not terribly impressive. I recall Biomira Theratope's (vaccine) survival times was very impressive for women with metastatic breast cancer. Also very sick women in that study. In OXO's case, the WF10 phase II study was also very impressive. Similarily, conducted with very sick AIDS/HIV patients. None the less, Virulizin does offer some positive effect on the macrophage to extend patient lives several months. It is encouraging that WF10 may modulate the macrophage better. In a tangent, when I wrote you the other day, in the back of my mind I was wondering (of course, in your opinion), how solid is WF10's patent and intellectual property? The results: Virulizin® Meta-Analysis Results Sixty-one patients were included in this analysis, with 49 classified as evaluable. The majority of these patients (87%) had received some form of treatment prior to entering these studies: 46 per cent receiving gemcitabine, 5-FU or other chemotherapeutic agents and 84 per cent had prior surgery. There was no difference in survival between patients who had or had no prior chemotherapy, but those who did not receive prior surgery had worse prognosis as compared to those who had prior surgery. Among the 61 eligible patients treated with Virulizin®, the median survival rate was 4.6 months. The six-month survival rate was 38 per cent and the nine-month survival rate was 25 per cent. In terms of evaluable patients (49 patients) the median survival rate was 5.7 months (95% C.I. from 4.6 months to 8.0 months) with six-month and nine-month survival rates of 48 per cent and 31 per cent, respectively. This result is better when compared to that of 63 patients who received gemcitabine as second line therapy after they had failed 5-FU as chemotherapy (Rothenberg et al.). The median survival in the Rothenberg study was approximately 3.8 months, with a six-month survival rate of 31 per cent and a nine-month survival of 15 per cent.